Clinical trial · no report yet · Phase 1
TROPION-Lung04
Phase 1b Study of Dato-DXd in Combination With Immunotherapy With or Without Carboplatin in Advanced or Metastatic Non-Small Cell Lung Cancer
- NCT04612751 ↗
- Active not recruiting
- AstraZeneca
- 28 commentary sources found
- Standard
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built.
| Channel | Found | |
|---|---|---|
| YouTube | 12 | |
| X threads | 9 | |
| Podcasts | 7 |
The trial
ClinicalTrials.gov- Official title
- A Phase 1b, Multicenter, 2-Part, Open-Label Study of Datopotamab Deruxtecan (Dato-DXd) in Combination With Immunotherapy With or Without Carboplatin in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer (Tropion-Lung04)
- Phase
- Phase 1
- Status
- Active not recruiting
- Conditions
- Advanced or Metastatic NSCLC
- Interventions
- Datopotamab deruxtecan; Durvalumab; Carboplatin; AZD2936; MEDI5752; AZD7789
- Arms
- Cohort 1 · Experimental
- Cohort 2 · Experimental
- Cohort 3 · Experimental
- Cohort 4 · Experimental
- Cohort 5 · Experimental
- Cohort 6 · Experimental
- Cohort 7 · Experimental
- Cohort 8 · Experimental
- Cohort 9 · Experimental
- Cohort 10 · Experimental
- Cohort 11 · Experimental
- Cohort 12 · Experimental
- Cohort 13 · Experimental
- Cohort 14 · Experimental
- Cohort 4A · Experimental
- Enrollment
- 155
- Primary outcomes
- Number of participants with DLTs; TEAEs and other safety parameters during the study.
- Sponsor
- AstraZeneca with Daiichi Sankyo
- Start
- Feb 2, 2021
- Primary completion
- May 4, 2026
- Results posted
- No
- Registry record
- NCT04612751 · updated Jul 27, 2026